On Wednesday, Health Care REIT, Inc. (NYSE:HCN)’s shares inclined 0.59% to $68.70.
Health Care REIT, Inc. (HCN) notified holders of its 3.00% Convertible Senior Notes due 2029 that they continue to be entitled to convert all or a portion of their Notes into cash and, if applicable, shares of the company’s common stock (the “Conversion Option”) through the close of business on September 30, 2015. The Notes remain convertible because the closing price of shares of the company’s common stock, for at least 20 trading days during the 30 successive trading-day period ending on June 30, 2015, was greater than 120% of the conversion price in effect on June 30, 2015.
To convert a certificated Note, a holder must (1) complete and sign a conversion notice, with appropriate signature guarantee, on the back of each Note, (2) surrender the Notes to The Bank of New York Mellon Trust Company, N.A., which is serving as the conversion agent, (3) furnish appropriate endorsements and transfer documents if required by the registrar or the conversion agent, (4) pay the amount of interest, if any, the holder must pay in accordance with the indenture, and (5) pay any tax or duty if required following the indenture. To convert interests in a global Note, the holder must comply with The Depository Trust Company’s (“DTC”) applicable conversion program procedures.
Upon conversion, the principal amount of the Notes will be paid in cash and the conversion value, if any, will be paid in shares of common stock based upon the volume-weighted average prices per share of the company’s common stock during the 20-trading day period following the satisfaction of the conversion procedures described above.
A holder may convert a portion of the Notes. The converted portion must be a principal amount of $1,000 or a multiple of $1,000.
Health Care REIT, Inc. is an independent equity real estate investment trust. The firm engages in acquiring, planning, developing, managing, repositioning and monetizing of real estate assets. It primarily invests in the real estate markets of the United States. The firm primarily invests in senior living and health care properties.
At the end of Wednesday’s trade, Credit Suisse Group AG (ADR) (NYSE:CS)‘s shares dipped -4.11% to $27.17.
Credit Suisse Group AG (ADR) (CS) driven by supply fundamentals and macroeconomic factors, according to Credit Suisse Asset Management.
The Bloomberg Commodity Index Total Return performance was negative for the month, with 15 out of 22 Index constituents trading lower.
Credit Suisse Asset Administration observed the following:
- Industrial Metals was the worst performing sector, down 7.70%, as a continued weak economic growth outlook for China weighed on demand expectations.
- Agriculture declined 3.50%, led lower by softs, as a weaker Brazilian Real incentivized exports of sugar, coffee and soybeans. In addition, heavy rainfall improved the coffee harvest outlook in Brazil and Colombia, increasing supply expectations.
- Energy finished the month 2.13% lower, led by Natural Gas. Inventories rose more than predictable towards the end of the month, and forecasts for moderate weather across the U.S. reduced cooling demand expectations.
- Livestock gained the most, up 2.34%. In addition to Lean Hogs, Live Cattle also ended the month higher following raised wholesale beef demand. Furthermore, good pasture conditions incentivized producers to hold back cattle, shrinking near term supplies.
Credit Suisse Group AG, together with its auxiliaries, provides various financial services to private, corporate, institutional, government clients, and high-net-worth individuals, in addition to affluent and retail clients worldwide.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), ended its Wednesday’s trading session with -1.33% loss, and closed at $60.73.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) declared the launch of generic Axert® (almotriptan malate) tablets, 6.25 mg and 12.5 mg, in the United States. Teva was the first applicant to submit an Abbreviated New Drug Application (ANDA) for almotriptan malate tablets containing a Paragraph IV patent certification.
The ANDA for almotriptan malate tablets presented by Teva to the US Food and Drug Administration on December 7, 2005, was the first ANDA presented by a generic company containing a Paragraph IV certification for Janssen Pharmaceuticals Axert®. Teva is the first applicant to receive approval and will have a period of market exclusivity until the pediatric exclusivity associated with the only patent for Axert® expires on November 7, 2015.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
